speb/financial-data huggingface dataset:
ADN.AX balance_sheet (annual, 2022-06-30) — Current Capital Lease Obligation: 165974.00
ADN.AX balance_sheet (annual, 2022-06-30) — Current Debt And Capital Lease Obligation: 165974.00
ADN.AX balance_sheet (annual, 2022-06-30) — Current Liabilities: 2317480.00
ADN.AX income_statement (annual, 2022-06-30) — Depreciation Amortization Depletion Income Statement: 191021.00
ADN.AX income_statement (annual, 2022-06-30) — Depreciation And Amortization In Income Statement: 191021.00
ADN.AX income_statement (annual, 2022-06-30) — Depreciation Income Statement: 191021.00
ADN.AX income_statement (annual, 2022-06-30) — Diluted Average Shares: 2661699070.00
ADN.AX income_statement (annual, 2022-06-30) — Diluted EPS: 0.00
ADN.AX income_statement (annual, 2022-06-30) — EBIT: -9137119.00
ADN.AX income_statement (annual, 2022-06-30) — EBITDA: -8946098.00
ADN.AX income_statement (annual, 2022-06-30) — Earnings From Equity Interest: -239537.00
ADN.AX balance_sheet (annual, 2022-06-30) — Employee Benefits: 35498.00
ADN.AX cash_flow (annual, 2022-06-30) — End Cash Position: 32853203.00
ADN.AX cash_flow (annual, 2022-06-30) — Financing Cash Flow: 42918096.00
ADN.AX cash_flow (annual, 2022-06-30) — Free Cash Flow: -10247935.00
ADN.AX balance_sheet (annual, 2022-06-30) — Gains Losses Not Affecting Retained Earnings: 6865285.00
ADN.AX income_statement (annual, 2022-06-30) — General And Administrative Expense: 5274987.00
ADN.AX balance_sheet (annual, 2022-06-30) — Gross PPE: 139724629.00
ADN.AX income_statement (annual, 2022-06-30) — Interest Income: 39297.00
ADN.AX income_statement (annual, 2022-06-30) — Interest Income Non Operating: 39297.00
ADN.AX cash_flow (annual, 2022-06-30) — Interest Paid Cff: -10206.00
ADN.AX cash_flow (annual, 2022-06-30) — Interest Received Cfi: 29380.00
ADN.AX balance_sheet (annual, 2022-06-30) — Invested Capital: 171190847.00
ADN.AX cash_flow (annual, 2022-06-30) — Investing Cash Flow: -9828651.00
ADN.AX balance_sheet (annual, 2022-06-30) — Investmentin Financial Assets: 46940.00
ADN.AX balance_sheet (annual, 2022-06-30) — Investments And Advances: 372224.00
ADN.AX cash_flow (annual, 2022-06-30) — Issuance Of Capital Stock: 45331913.00
ADN.AX balance_sheet (annual, 2022-06-30) — Land And Improvements: 736180.00
ADN.AX balance_sheet (annual, 2022-06-30) — Long Term Capital Lease Obligation: 680163.00
ADN.AX balance_sheet (annual, 2022-06-30) — Long Term Debt And Capital Lease Obligation: 680163.00
ADN.AX balance_sheet (annual, 2022-06-30) — Machinery Furniture Equipment: 616176.00
ADN.AX cash_flow (annual, 2022-06-30) — Net Common Stock Issuance: 43028097.00
ADN.AX income_statement (annual, 2022-06-30) — Net Income: -8733119.00
ADN.AX income_statement (annual, 2022-06-30) — Net Income Common Stockholders: -8733119.00
ADN.AX income_statement (annual, 2022-06-30) — Net Income Continuous Operations: -8733119.00
ADN.AX income_statement (annual, 2022-06-30) — Net Income From Continuing And Discontinued Operation: -8733119.00
ADN.AX income_statement (annual, 2022-06-30) — Net Income From Continuing Operation Net Minority Interest: -8733119.00
ADN.AX income_statement (annual, 2022-06-30) — Net Income Including Noncontrolling Interests: -8733119.00
ADN.AX income_statement (annual, 2022-06-30) — Net Interest Income: 39297.00
ADN.AX cash_flow (annual, 2022-06-30) — Net Investment Purchase And Sale: -382483.00
ADN.AX income_statement (annual, 2022-06-30) — Net Non Operating Interest Income Expense: 39297.00
ADN.AX cash_flow (annual, 2022-06-30) — Net Other Financing Charges: -199590.00
ADN.AX cash_flow (annual, 2022-06-30) — Net Other Investing Changes: -4368574.00
ADN.AX balance_sheet (annual, 2022-06-30) — Net PPE: 139501350.00
ADN.AX cash_flow (annual, 2022-06-30) — Net PPE Purchase And Sale: -1070991.00
ADN.AX balance_sheet (annual, 2022-06-30) — Net Tangible Assets: 171190847.00
ADN.AX balance_sheet (annual, 2022-06-30) — Non Current Pension And Other Postretirement Benefit Plans: 35498.00
ADN.AX income_statement (annual, 2022-06-30) — Normalized EBITDA: -8946098.00
ADN.AX income_statement (annual, 2022-06-30) — Normalized Income: -8733119.00
ADN.AX income_statement (annual, 2022-06-30) — Operating Income: -9137119.00
ADN.AX balance_sheet (annual, 2022-06-30) — Ordinary Shares Number: 3105900932.00
ADN.AX balance_sheet (annual, 2022-06-30) — Other Equity Adjustments: 6865285.00
ADN.AX income_statement (annual, 2022-06-30) — Other Gand A: 2197525.00
ADN.AX income_statement (annual, 2022-06-30) — Other Income Expense: 173682.00
ADN.AX balance_sheet (annual, 2022-06-30) — Other Investments: 325284.00
ADN.AX income_statement (annual, 2022-06-30) — Other Non Operating Income Expenses: 413219.00
ADN.AX income_statement (annual, 2022-06-30) — Other Operating Expenses: 2733972.00
ADN.AX balance_sheet (annual, 2022-06-30) — Other Properties: 138280101.00
ADN.AX balance_sheet (annual, 2022-06-30) — Other Receivables: 1247211.00
ADN.AX balance_sheet (annual, 2022-06-30) — Payables: 1966169.00
ADN.AX balance_sheet (annual, 2022-06-30) — Payables And Accrued Expenses: 1966169.00
ADN.AX cash_flow (annual, 2022-06-30) — Paymentsto Suppliersfor Goodsand Services: -5140961.00
ADN.AX balance_sheet (annual, 2022-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 185337.00
ADN.AX income_statement (annual, 2022-06-30) — Pretax Income: -8733119.00
ADN.AX cash_flow (annual, 2022-06-30) — Purchase Of Investment: -382483.00
ADN.AX cash_flow (annual, 2022-06-30) — Purchase Of PPE: -1070991.00
ADN.AX balance_sheet (annual, 2022-06-30) — Receivables: 1247211.00
ADN.AX income_statement (annual, 2022-06-30) — Reconciled Depreciation: 191021.00
ADN.AX income_statement (annual, 2022-06-30) — Rent And Landing Fees: 78171.00
ADN.AX cash_flow (annual, 2022-06-30) — Repurchase Of Capital Stock: -2303816.00
ADN.AX income_statement (annual, 2022-06-30) — Research And Development: 846464.00
ADN.AX balance_sheet (annual, 2022-06-30) — Retained Earnings: -54924558.00
ADN.AX income_statement (annual, 2022-06-30) — Salaries And Wages: 2999291.00
ADN.AX income_statement (annual, 2022-06-30) — Selling And Marketing Expense: 90675.00
ADN.AX income_statement (annual, 2022-06-30) — Selling General And Administration: 5365662.00
ADN.AX balance_sheet (annual, 2022-06-30) — Share Issued: 3105900932.00
ADN.AX balance_sheet (annual, 2022-06-30) — Stockholders Equity: 171190847.00
ADN.AX balance_sheet (annual, 2022-06-30) — Tangible Book Value: 171190847.00
ADN.AX income_statement (annual, 2022-06-30) — Tax Effect Of Unusual Items: 0.00
ADN.AX income_statement (annual, 2022-06-30) — Tax Provision: 0.00
ADN.AX income_statement (annual, 2022-06-30) — Tax Rate For Calcs: 0.00
ADN.AX balance_sheet (annual, 2022-06-30) — Total Assets: 174223988.00
ADN.AX balance_sheet (annual, 2022-06-30) — Total Capitalization: 171190847.00
ADN.AX balance_sheet (annual, 2022-06-30) — Total Debt: 846137.00
ADN.AX balance_sheet (annual, 2022-06-30) — Total Equity Gross Minority Interest: 171190847.00
ADN.AX balance_sheet (annual, 2022-06-30) — Total Liabilities Net Minority Interest: 3033141.00
ADN.AX balance_sheet (annual, 2022-06-30) — Total Non Current Assets: 139873574.00
ADN.AX balance_sheet (annual, 2022-06-30) — Total Non Current Liabilities Net Minority Interest: 715661.00
ADN.AX balance_sheet (annual, 2022-06-30) — Trading Securities: 46940.00
ADN.AX balance_sheet (annual, 2022-06-30) — Working Capital: 32032934.00
ADN.AX income_statement (annual, 2023-06-30) — +Operating Expense: 11888121.00
ADN.AX balance_sheet (annual, 2023-06-30) — Accounts Payable: 1730341.00
ADN.AX balance_sheet (annual, 2023-06-30) — Accumulated Depreciation: -648001.00
ADN.AX balance_sheet (annual, 2023-06-30) — Assets Held For Sale Current: 1750000.00
ADN.AX income_statement (annual, 2023-06-30) — Basic Average Shares: 3109993603.00
ADN.AX income_statement (annual, 2023-06-30) — Basic EPS: 0.00
ADN.AX cash_flow (annual, 2023-06-30) — Beginning Cash Position: 32853203.00
ADN.AX cash_flow (annual, 2023-06-30) — Capital Expenditure: -8598020.00
ADN.AX cash_flow (annual, 2023-06-30) — Capital Expenditure Reported: -7521335.00
ADN.AX balance_sheet (annual, 2023-06-30) — Capital Lease Obligations: 727116.00
ADN.AX balance_sheet (annual, 2023-06-30) — Capital Stock: 219882120.00
ADN.AX balance_sheet (annual, 2023-06-30) — Cash And Cash Equivalents: 15300890.00
ADN.AX balance_sheet (annual, 2023-06-30) — Cash Cash Equivalents And Short Term Investments: 15300890.00
ADN.AX balance_sheet (annual, 2023-06-30) — Cash Equivalents: 0.00
ADN.AX balance_sheet (annual, 2023-06-30) — Cash Financial: 15300890.00
ADN.AX cash_flow (annual, 2023-06-30) — Cash Flow From Continuing Financing Activities: -224380.00
ADN.AX cash_flow (annual, 2023-06-30) — Cash Flow From Continuing Investing Activities: -8193143.00
ADN.AX cash_flow (annual, 2023-06-30) — Cash Flowsfromusedin Operating Activities Direct: -9134790.00
ADN.AX cash_flow (annual, 2023-06-30) — Changes In Cash: -17552313.00
ADN.AX cash_flow (annual, 2023-06-30) — Classesof Cash Payments: -9488392.00
ADN.AX cash_flow (annual, 2023-06-30) — Classesof Cash Receiptsfrom Operating Activities: 353602.00
ADN.AX balance_sheet (annual, 2023-06-30) — Common Stock: 219882120.00
ADN.AX balance_sheet (annual, 2023-06-30) — Common Stock Equity: 162156843.00
ADN.AX balance_sheet (annual, 2023-06-30) — Construction In Progress: 722829.00
ADN.AX balance_sheet (annual, 2023-06-30) — Current Assets: 19891911.00
ADN.AX balance_sheet (annual, 2023-06-30) — Current Capital Lease Obligation: 200576.00
ADN.AX balance_sheet (annual, 2023-06-30) — Current Debt And Capital Lease Obligation: 200576.00
ADN.AX balance_sheet (annual, 2023-06-30) — Current Liabilities: 2240628.00
ADN.AX income_statement (annual, 2023-06-30) — Depreciation Amortization Depletion Income Statement: 424722.00
ADN.AX income_statement (annual, 2023-06-30) — Depreciation And Amortization In Income Statement: 424722.00
ADN.AX income_statement (annual, 2023-06-30) — Depreciation Income Statement: 424722.00
ADN.AX income_statement (annual, 2023-06-30) — Diluted Average Shares: 3109993603.00
ADN.AX income_statement (annual, 2023-06-30) — Diluted EPS: 0.00
ADN.AX income_statement (annual, 2023-06-30) — EBIT: -11888121.00
ADN.AX income_statement (annual, 2023-06-30) — EBITDA: -11463399.00
ADN.AX balance_sheet (annual, 2023-06-30) — Employee Benefits: 51480.00
ADN.AX cash_flow (annual, 2023-06-30) — End Cash Position: 15300890.00
ADN.AX cash_flow (annual, 2023-06-30) — Financing Cash Flow: -224380.00
ADN.AX cash_flow (annual, 2023-06-30) — Free Cash Flow: -17732810.00
ADN.AX balance_sheet (annual, 2023-06-30) — Gains Losses Not Affecting Retained Earnings: 5213883.00
ADN.AX income_statement (annual, 2023-06-30) — General And Administrative Expense: 5410889.00
ADN.AX balance_sheet (annual, 2023-06-30) — Gross PPE: 145486474.00
ADN.AX income_statement (annual, 2023-06-30) — Interest Income: 459521.00
ADN.AX income_statement (annual, 2023-06-30) — Interest Income Non Operating: 459521.00
ADN.AX cash_flow (annual, 2023-06-30) — Interest Paid Cff: -27374.00
ADN.AX cash_flow (annual, 2023-06-30) — Interest Received Cfi: 382353.00
ADN.AX balance_sheet (annual, 2023-06-30) — Invested Capital: 162156843.00
ADN.AX cash_flow (annual, 2023-06-30) — Investing Cash Flow: -8193143.00
ADN.AX balance_sheet (annual, 2023-06-30) — Investmentin Financial Assets: 12250.00
ADN.AX balance_sheet (annual, 2023-06-30) — Investments And Advances: 300107.00
ADN.AX balance_sheet (annual, 2023-06-30) — Land And Improvements: 736180.00
ADN.AX balance_sheet (annual, 2023-06-30) — Leases: 84104.00
ADN.AX balance_sheet (annual, 2023-06-30) — Long Term Capital Lease Obligation: 526540.00
ADN.AX balance_sheet (annual, 2023-06-30) — Long Term Debt And Capital Lease Obligation: 526540.00
ADN.AX balance_sheet (annual, 2023-06-30) — Long Term Provisions: 55000.00
ADN.AX balance_sheet (annual, 2023-06-30) — Machinery Furniture Equipment: 683045.00
ADN.AX income_statement (annual, 2023-06-30) — Net Income: -9461246.00
ADN.AX income_statement (annual, 2023-06-30) — Net Income Common Stockholders: -9461246.00
ADN.AX income_statement (annual, 2023-06-30) — Net Income Continuous Operations: -9461246.00
ADN.AX income_statement (annual, 2023-06-30) — Net Income From Continuing And Discontinued Operation: -9461246.00
ADN.AX income_statement (annual, 2023-06-30) — Net Income From Continuing Operation Net Minority Interest: -9461246.00
ADN.AX income_statement (annual, 2023-06-30) — Net Income Including Noncontrolling Interests: -9461246.00
ADN.AX income_statement (annual, 2023-06-30) — Net Interest Income: 459521.00
ADN.AX cash_flow (annual, 2023-06-30) — Net Investment Purchase And Sale: 32524.00
ADN.AX income_statement (annual, 2023-06-30) — Net Non Operating Interest Income Expense: 459521.00
ADN.AX cash_flow (annual, 2023-06-30) — Net Other Financing Charges: -394012.00
ADN.AX cash_flow (annual, 2023-06-30) — Net Other Investing Changes: -10000.00
ADN.AX balance_sheet (annual, 2023-06-30) — Net PPE: 144838473.00
ADN.AX cash_flow (annual, 2023-06-30) — Net PPE Purchase And Sale: -1076685.00
ADN.AX balance_sheet (annual, 2023-06-30) — Net Tangible Assets: 162156843.00
ADN.AX balance_sheet (annual, 2023-06-30) — Non Current Pension And Other Postretirement Benefit Plans: 51480.00
ADN.AX income_statement (annual, 2023-06-30) — Normalized EBITDA: -11463399.00
ADN.AX income_statement (annual, 2023-06-30) — Normalized Income: -9461246.00
ADN.AX income_statement (annual, 2023-06-30) — Operating Income: -11888121.00
ADN.AX balance_sheet (annual, 2023-06-30) — Ordinary Shares Number: 3108163432.00
ADN.AX cash_flow (annual, 2023-06-30) — Other Cash Receiptsfrom Operating Activities: 353602.00
ADN.AX balance_sheet (annual, 2023-06-30) — Other Equity Adjustments: 5213883.00
ADN.AX income_statement (annual, 2023-06-30) — Other Gand A: 2158334.00
ADN.AX income_statement (annual, 2023-06-30) — Other Income Expense: 1542632.00
ADN.AX balance_sheet (annual, 2023-06-30) — Other Investments: 287857.00
ADN.AX income_statement (annual, 2023-06-30) — Other Non Operating Income Expenses: 1542632.00
ADN.AX income_statement (annual, 2023-06-30) — Other Operating Expenses: 3128817.00
ADN.AX balance_sheet (annual, 2023-06-30) — Other Properties: 143260316.00
ADN.AX balance_sheet (annual, 2023-06-30) — Other Receivables: 2841021.00
ADN.AX balance_sheet (annual, 2023-06-30) — Payables: 1730341.00
ADN.AX balance_sheet (annual, 2023-06-30) — Payables And Accrued Expenses: 1730341.00
ADN.AX cash_flow (annual, 2023-06-30) — Paymentsto Suppliersfor Goodsand Services: -9488392.00
ADN.AX balance_sheet (annual, 2023-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 309711.00
ADN.AX income_statement (annual, 2023-06-30) — Pretax Income: -9461246.00
ADN.AX cash_flow (annual, 2023-06-30) — Purchase Of PPE: -1076685.00
ADN.AX balance_sheet (annual, 2023-06-30) — Receivables: 2841021.00
ADN.AX income_statement (annual, 2023-06-30) — Reconciled Depreciation: 424722.00
ADN.AX income_statement (annual, 2023-06-30) — Rent And Landing Fees: 25477.00
ADN.AX income_statement (annual, 2023-06-30) — Research And Development: 2838533.00
ADN.AX balance_sheet (annual, 2023-06-30) — Retained Earnings: -62939160.00
ADN.AX income_statement (annual, 2023-06-30) — Salaries And Wages: 3227078.00
ADN.AX cash_flow (annual, 2023-06-30) — Sale Of Investment: 32524.00
ADN.AX income_statement (annual, 2023-06-30) — Selling And Marketing Expense: 85160.00
ADN.AX income_statement (annual, 2023-06-30) — Selling General And Administration: 5496049.00
ADN.AX balance_sheet (annual, 2023-06-30) — Share Issued: 3108163432.00
ADN.AX balance_sheet (annual, 2023-06-30) — Stockholders Equity: 162156843.00
ADN.AX balance_sheet (annual, 2023-06-30) — Tangible Book Value: 162156843.00
ADN.AX income_statement (annual, 2023-06-30) — Tax Effect Of Unusual Items: 0.00
ADN.AX income_statement (annual, 2023-06-30) — Tax Provision: 0.00
ADN.AX income_statement (annual, 2023-06-30) — Tax Rate For Calcs: 0.00
ADN.AX balance_sheet (annual, 2023-06-30) — Total Assets: 165030491.00
ADN.AX balance_sheet (annual, 2023-06-30) — Total Capitalization: 162156843.00
ADN.AX balance_sheet (annual, 2023-06-30) — Total Debt: 727116.00
ADN.AX balance_sheet (annual, 2023-06-30) — Total Equity Gross Minority Interest: 162156843.00
ADN.AX balance_sheet (annual, 2023-06-30) — Total Liabilities Net Minority Interest: 2873648.00
ADN.AX balance_sheet (annual, 2023-06-30) — Total Non Current Assets: 145138580.00
ADN.AX balance_sheet (annual, 2023-06-30) — Total Non Current Liabilities Net Minority Interest: 633020.00
ADN.AX balance_sheet (annual, 2023-06-30) — Trading Securities: 12250.00
ADN.AX balance_sheet (annual, 2023-06-30) — Working Capital: 17651283.00
ADN.AX income_statement (annual, 2024-06-30) — +Operating Expense: 8790247.00
ADN.AX balance_sheet (annual, 2024-06-30) — Accounts Payable: 2250227.00
ADN.AX balance_sheet (annual, 2024-06-30) — Accumulated Depreciation: -1138816.00
ADN.AX income_statement (annual, 2024-06-30) — Basic Average Shares: 3110270932.00
ADN.AX income_statement (annual, 2024-06-30) — Basic EPS: 0.00
ADN.AX cash_flow (annual, 2024-06-30) — Beginning Cash Position: 15300890.00
ADN.AX cash_flow (annual, 2024-06-30) — Capital Expenditure: -7895436.00
ADN.AX cash_flow (annual, 2024-06-30) — Capital Expenditure Reported: -4835139.00
ADN.AX balance_sheet (annual, 2024-06-30) — Capital Lease Obligations: 581335.00
ADN.AX balance_sheet (annual, 2024-06-30) — Capital Stock: 219882120.00
ADN.AX balance_sheet (annual, 2024-06-30) — Cash And Cash Equivalents: 5436262.00
ADN.AX balance_sheet (annual, 2024-06-30) — Cash Cash Equivalents And Short Term Investments: 5436262.00
ADN.AX balance_sheet (annual, 2024-06-30) — Cash Financial: 5436262.00
ADN.AX cash_flow (annual, 2024-06-30) — Cash Flow From Continuing Financing Activities: -247601.00
ADN.AX cash_flow (annual, 2024-06-30) — Cash Flow From Continuing Investing Activities: -4564644.00
ADN.AX cash_flow (annual, 2024-06-30) — Cash Flowsfromusedin Operating Activities Direct: -5052383.00
ADN.AX cash_flow (annual, 2024-06-30) — Changes In Cash: -9864628.00
ADN.AX cash_flow (annual, 2024-06-30) — Classesof Cash Payments: -7119762.00
ADN.AX cash_flow (annual, 2024-06-30) — Classesof Cash Receiptsfrom Operating Activities: 2067379.00
ADN.AX balance_sheet (annual, 2024-06-30) — Common Stock: 219882120.00
ADN.AX balance_sheet (annual, 2024-06-30) — Common Stock Equity: 154875934.00
ADN.AX balance_sheet (annual, 2024-06-30) — Construction In Progress: 3223233.00
ADN.AX balance_sheet (annual, 2024-06-30) — Current Assets: 6142403.00
ADN.AX balance_sheet (annual, 2024-06-30) — Current Capital Lease Obligation: 215898.00
ADN.AX balance_sheet (annual, 2024-06-30) — Current Debt And Capital Lease Obligation: 215898.00
ADN.AX balance_sheet (annual, 2024-06-30) — Current Liabilities: 2717237.00
ADN.AX income_statement (annual, 2024-06-30) — Depreciation Amortization Depletion Income Statement: 490815.00
ADN.AX income_statement (annual, 2024-06-30) — Depreciation And Amortization In Income Statement: 490815.00
ADN.AX income_statement (annual, 2024-06-30) — Depreciation Income Statement: 490815.00
ADN.AX income_statement (annual, 2024-06-30) — Diluted Average Shares: 3110270932.00
ADN.AX income_statement (annual, 2024-06-30) — Diluted EPS: 0.00
ADN.AX income_statement (annual, 2024-06-30) — EBIT: -8790247.00
ADN.AX income_statement (annual, 2024-06-30) — EBITDA: -8299432.00
ADN.AX balance_sheet (annual, 2024-06-30) — Employee Benefits: 54407.00
ADN.AX cash_flow (annual, 2024-06-30) — End Cash Position: 5436262.00
ADN.AX cash_flow (annual, 2024-06-30) — Financing Cash Flow: -247601.00
ADN.AX cash_flow (annual, 2024-06-30) — Free Cash Flow: -12947819.00
ADN.AX balance_sheet (annual, 2024-06-30) — Gains Losses Not Affecting Retained Earnings: 1132222.00
ADN.AX income_statement (annual, 2024-06-30) — General And Administrative Expense: 4785563.00
ADN.AX balance_sheet (annual, 2024-06-30) — Gross PPE: 151075125.00
ADN.AX income_statement (annual, 2024-06-30) — Interest Income: 214371.00
ADN.AX income_statement (annual, 2024-06-30) — Interest Income Non Operating: 214371.00
ADN.AX cash_flow (annual, 2024-06-30) — Interest Paid Cff: -21057.00
ADN.AX cash_flow (annual, 2024-06-30) — Interest Received Cfi: 297036.00
ADN.AX balance_sheet (annual, 2024-06-30) — Invested Capital: 154875934.00
ADN.AX cash_flow (annual, 2024-06-30) — Investing Cash Flow: -4564644.00
ADN.AX balance_sheet (annual, 2024-06-30) — Investmentin Financial Assets: 1708280.00
ADN.AX balance_sheet (annual, 2024-06-30) — Investments And Advances: 1989303.00
ADN.AX balance_sheet (annual, 2024-06-30) — Land And Improvements: 1705961.00
ADN.AX balance_sheet (annual, 2024-06-30) — Leases: 84104.00
ADN.AX balance_sheet (annual, 2024-06-30) — Long Term Capital Lease Obligation: 365437.00
ADN.AX balance_sheet (annual, 2024-06-30) — Long Term Debt And Capital Lease Obligation: 365437.00
ADN.AX balance_sheet (annual, 2024-06-30) — Long Term Provisions: 55000.00
ADN.AX balance_sheet (annual, 2024-06-30) — Machinery Furniture Equipment: 839686.00
ADN.AX income_statement (annual, 2024-06-30) — Net Income: -7269156.00
ADN.AX income_statement (annual, 2024-06-30) — Net Income Common Stockholders: -7269156.00
ADN.AX income_statement (annual, 2024-06-30) — Net Income Continuous Operations: -7269156.00
ADN.AX income_statement (annual, 2024-06-30) — Net Income From Continuing And Discontinued Operation: -7269156.00
ADN.AX income_statement (annual, 2024-06-30) — Net Income From Continuing Operation Net Minority Interest: -7269156.00
ADN.AX income_statement (annual, 2024-06-30) — Net Income Including Noncontrolling Interests: -7269156.00
ADN.AX income_statement (annual, 2024-06-30) — Net Interest Income: 214371.00
ADN.AX income_statement (annual, 2024-06-30) — Net Non Operating Interest Income Expense: 214371.00
ADN.AX cash_flow (annual, 2024-06-30) — Net Other Financing Charges: -453088.00
ADN.AX cash_flow (annual, 2024-06-30) — Net Other Investing Changes: 2483756.00
ADN.AX balance_sheet (annual, 2024-06-30) — Net PPE: 149936309.00
ADN.AX cash_flow (annual, 2024-06-30) — Net PPE Purchase And Sale: -2510297.00
ADN.AX balance_sheet (annual, 2024-06-30) — Net Tangible Assets: 154875934.00
ADN.AX balance_sheet (annual, 2024-06-30) — Non Current Pension And Other Postretirement Benefit Plans: 54407.00
ADN.AX income_statement (annual, 2024-06-30) — Normalized EBITDA: -8299432.00
ADN.AX income_statement (annual, 2024-06-30) — Normalized Income: -7269156.00
ADN.AX income_statement (annual, 2024-06-30) — Operating Income: -8790247.00
ADN.AX balance_sheet (annual, 2024-06-30) — Ordinary Shares Number: 3108163432.00
ADN.AX cash_flow (annual, 2024-06-30) — Other Cash Receiptsfrom Operating Activities: 2067379.00
ADN.AX balance_sheet (annual, 2024-06-30) — Other Equity Adjustments: 1132222.00
ADN.AX income_statement (annual, 2024-06-30) — Other Gand A: 1818991.00
ADN.AX income_statement (annual, 2024-06-30) — Other Income Expense: 815905.00
ADN.AX balance_sheet (annual, 2024-06-30) — Other Investments: 281023.00
ADN.AX income_statement (annual, 2024-06-30) — Other Non Operating Income Expenses: 815905.00
ADN.AX income_statement (annual, 2024-06-30) — Other Operating Expenses: 2627136.00
ADN.AX balance_sheet (annual, 2024-06-30) — Other Properties: 145222141.00
ADN.AX balance_sheet (annual, 2024-06-30) — Other Receivables: 449861.00
ADN.AX balance_sheet (annual, 2024-06-30) — Payables: 2250227.00
ADN.AX balance_sheet (annual, 2024-06-30) — Payables And Accrued Expenses: 2250227.00
ADN.AX cash_flow (annual, 2024-06-30) — Paymentsto Suppliersfor Goodsand Services: -7119762.00
ADN.AX balance_sheet (annual, 2024-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 251112.00
ADN.AX balance_sheet (annual, 2024-06-30) — Prepaid Assets: 256280.00
ADN.AX income_statement (annual, 2024-06-30) — Pretax Income: -7269156.00
ADN.AX cash_flow (annual, 2024-06-30) — Purchase Of PPE: -3060297.00
ADN.AX balance_sheet (annual, 2024-06-30) — Receivables: 449861.00
ADN.AX income_statement (annual, 2024-06-30) — Reconciled Depreciation: 490815.00
ADN.AX income_statement (annual, 2024-06-30) — Rent And Landing Fees: 2099.00
ADN.AX income_statement (annual, 2024-06-30) — Research And Development: 821124.00
ADN.AX balance_sheet (annual, 2024-06-30) — Retained Earnings: -66138408.00
ADN.AX income_statement (annual, 2024-06-30) — Salaries And Wages: 2964473.00
ADN.AX cash_flow (annual, 2024-06-30) — Sale Of PPE: 550000.00
ADN.AX income_statement (annual, 2024-06-30) — Selling And Marketing Expense: 65609.00
ADN.AX income_statement (annual, 2024-06-30) — Selling General And Administration: 4851172.00
ADN.AX balance_sheet (annual, 2024-06-30) — Share Issued: 3108163432.00
ADN.AX balance_sheet (annual, 2024-06-30) — Stockholders Equity: 154875934.00
ADN.AX balance_sheet (annual, 2024-06-30) — Tangible Book Value: 154875934.00
ADN.AX income_statement (annual, 2024-06-30) — Tax Effect Of Unusual Items: 0.00
ADN.AX income_statement (annual, 2024-06-30) — Tax Provision: 0.00
ADN.AX income_statement (annual, 2024-06-30) — Tax Rate For Calcs: 0.00
ADN.AX balance_sheet (annual, 2024-06-30) — Total Assets: 158068015.00
ADN.AX balance_sheet (annual, 2024-06-30) — Total Capitalization: 154875934.00
ADN.AX balance_sheet (annual, 2024-06-30) — Total Debt: 581335.00
ADN.AX balance_sheet (annual, 2024-06-30) — Total Equity Gross Minority Interest: 154875934.00
ADN.AX balance_sheet (annual, 2024-06-30) — Total Liabilities Net Minority Interest: 3192081.00
ADN.AX balance_sheet (annual, 2024-06-30) — Total Non Current Assets: 151925612.00
ADN.AX balance_sheet (annual, 2024-06-30) — Total Non Current Liabilities Net Minority Interest: 474844.00
ADN.AX balance_sheet (annual, 2024-06-30) — Trading Securities: 1708280.00
ADN.AX balance_sheet (annual, 2024-06-30) — Working Capital: 3425166.00
ADN.TO cash_flow (annual, 2021-12-31) — Capital Expenditure: -333000.00
ADN.TO income_statement (annual, 2021-12-31) — Depreciation Amortization Depletion Income Statement: 261000.00
ADN.TO income_statement (annual, 2021-12-31) — Depreciation And Amortization In Income Statement: 261000.00
ADN.TO cash_flow (annual, 2021-12-31) — Net Foreign Currency Exchange Gain Loss: -432000.00
ADN.TO cash_flow (annual, 2021-12-31) — Net Other Investing Changes: -333000.00
ADN.TO cash_flow (annual, 2021-12-31) — Other Non Cash Items: -6773000.00
ADN.TO income_statement (annual, 2021-12-31) — Other Non Operating Income Expenses: 6773000.00
ADN.TO cash_flow (annual, 2021-12-31) — Purchase Of PPE: -333000.00
ADN.TO balance_sheet (annual, 2021-12-31) — Taxes Receivable: 104000.00
ADN.TO income_statement (annual, 2022-12-31) — +Operating Expense: 9714000.00
ADN.TO income_statement (annual, 2022-12-31) — +Total Revenue: 90473000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Accounts Payable: 11206000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Accounts Receivable: 8265000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -4511000.00
ADN.TO income_statement (annual, 2022-12-31) — Basic Average Shares: 16791973.00
ADN.TO income_statement (annual, 2022-12-31) — Basic EPS: 2.11
ADN.TO cash_flow (annual, 2022-12-31) — Beginning Cash Position: 7316000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Capital Stock: 142765000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 6230000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 6230000.00
ADN.TO cash_flow (annual, 2022-12-31) — Cash Dividends Paid: -16002000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Cash Financial: 6230000.00
ADN.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: -16002000.00
ADN.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -319000.00
ADN.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: 15235000.00
ADN.TO cash_flow (annual, 2022-12-31) — Change In Inventory: -400000.00
ADN.TO cash_flow (annual, 2022-12-31) — Change In Other Working Capital: 570000.00
ADN.TO cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 2406000.00
ADN.TO cash_flow (annual, 2022-12-31) — Change In Receivables: 121000.00
ADN.TO cash_flow (annual, 2022-12-31) — Change In Working Capital: 2697000.00
ADN.TO cash_flow (annual, 2022-12-31) — Changes In Account Receivables: 121000.00
ADN.TO cash_flow (annual, 2022-12-31) — Changes In Cash: -1086000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Common Stock: 142765000.00
ADN.TO cash_flow (annual, 2022-12-31) — Common Stock Dividend Paid: -16002000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Common Stock Equity: 303723000.00
ADN.TO income_statement (annual, 2022-12-31) — Cost Of Revenue: 62894000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Current Assets: 16345000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Current Liabilities: 16123000.00
ADN.TO cash_flow (annual, 2022-12-31) — Deferred Income Tax: 13627000.00
ADN.TO cash_flow (annual, 2022-12-31) — Deferred Tax: 13627000.00
ADN.TO cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 273000.00
ADN.TO income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 273000.00
ADN.TO cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 273000.00
ADN.TO income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 273000.00
ADN.TO income_statement (annual, 2022-12-31) — Diluted Average Shares: 16791973.00
ADN.TO income_statement (annual, 2022-12-31) — Diluted EPS: 2.11
ADN.TO income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 35507000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Dividends Payable: 4897000.00
ADN.TO income_statement (annual, 2022-12-31) — EBIT: 52232000.00
ADN.TO income_statement (annual, 2022-12-31) — EBITDA: 52505000.00
ADN.TO cash_flow (annual, 2022-12-31) — End Cash Position: 6230000.00
ADN.TO cash_flow (annual, 2022-12-31) — Financing Cash Flow: -16002000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Fixed Assets Revaluation Reserve: 31345000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Foreign Currency Translation Adjustments: 27621000.00
ADN.TO cash_flow (annual, 2022-12-31) — Free Cash Flow: 15235000.00
ADN.TO cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: -34311000.00
ADN.TO cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: -56000.00
ADN.TO income_statement (annual, 2022-12-31) — Gain On Sale Of Ppe: 56000.00
ADN.TO income_statement (annual, 2022-12-31) — Gain On Sale Of Security: 34311000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: 58966000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 6140000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Gross PPE: 92497000.00
ADN.TO income_statement (annual, 2022-12-31) — Gross Profit: 27579000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Income Tax Payable: 20000.00
ADN.TO income_statement (annual, 2022-12-31) — Interest Expense: 3098000.00
ADN.TO income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 3098000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Inventory: 1850000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Invested Capital: 411660000.00
ADN.TO cash_flow (annual, 2022-12-31) — Investing Cash Flow: -319000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Land And Improvements: 89671000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Long Term Debt: 107937000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 107937000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Net Debt: 101707000.00
ADN.TO cash_flow (annual, 2022-12-31) — Net Foreign Currency Exchange Gain Loss: 0.00
ADN.TO income_statement (annual, 2022-12-31) — Net Income: 35507000.00
ADN.TO income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 35507000.00
ADN.TO income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 35507000.00
ADN.TO income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 35507000.00
ADN.TO income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 35507000.00
ADN.TO cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 35507000.00
ADN.TO income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 35507000.00
ADN.TO income_statement (annual, 2022-12-31) — Net Interest Income: -3098000.00
ADN.TO income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -3098000.00
ADN.TO cash_flow (annual, 2022-12-31) — Net Other Investing Changes: -378000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Net PPE: 87986000.00
ADN.TO cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: 59000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 297583000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 120053000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 120053000.00
ADN.TO income_statement (annual, 2022-12-31) — Normalized EBITDA: 18138000.00
ADN.TO income_statement (annual, 2022-12-31) — Normalized Income: 10671467.19
ADN.TO cash_flow (annual, 2022-12-31) — Operating Cash Flow: 15235000.00
ADN.TO cash_flow (annual, 2022-12-31) — Operating Gains Losses: -34367000.00
ADN.TO income_statement (annual, 2022-12-31) — Operating Income: 17865000.00
ADN.TO income_statement (annual, 2022-12-31) — Operating Revenue: 90473000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 16958881.00
ADN.TO income_statement (annual, 2022-12-31) — Other Income Expense: 34367000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Other Inventories: 1850000.00
ADN.TO cash_flow (annual, 2022-12-31) — Other Non Cash Items: -34311000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 437365000.00
ADN.TO income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: 34311000.00
ADN.TO income_statement (annual, 2022-12-31) — Other Operating Expenses: 1375000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Other Properties: 2826000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Payables: 16123000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 16123000.00
ADN.TO income_statement (annual, 2022-12-31) — Pretax Income: 49134000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Properties: 0.00
ADN.TO balance_sheet (annual, 2022-12-31) — Receivables: 8265000.00
ADN.TO income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 62894000.00
ADN.TO income_statement (annual, 2022-12-31) — Reconciled Depreciation: 273000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Retained Earnings: 101992000.00
ADN.TO cash_flow (annual, 2022-12-31) — Sale Of PPE: 59000.00
ADN.TO income_statement (annual, 2022-12-31) — Selling General And Administration: 8066000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Share Issued: 16958881.00
ADN.TO income_statement (annual, 2022-12-31) — Special Income Charges: 56000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Stockholders Equity: 303723000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Tangible Book Value: 297583000.00
ADN.TO income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 9531467.19
ADN.TO income_statement (annual, 2022-12-31) — Tax Provision: 13627000.00
ADN.TO income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.28
ADN.TO balance_sheet (annual, 2022-12-31) — Taxes Receivable: 0.00
ADN.TO cash_flow (annual, 2022-12-31) — Taxes Refund Paid: -2502000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Total Assets: 547836000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Total Capitalization: 411660000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Total Debt: 107937000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 303723000.00
ADN.TO income_statement (annual, 2022-12-31) — Total Expenses: 72608000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 244113000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 531491000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 227990000.00
ADN.TO income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 17865000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Total Tax Payable: 20000.00
ADN.TO income_statement (annual, 2022-12-31) — Total Unusual Items: 34367000.00
ADN.TO income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 34367000.00
ADN.TO balance_sheet (annual, 2022-12-31) — Working Capital: 222000.00
ADN.TO income_statement (annual, 2023-12-31) — +Operating Expense: 10016000.00
ADN.TO income_statement (annual, 2023-12-31) — +Total Revenue: 93477000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Accounts Payable: 9370000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Accounts Receivable: 9301000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -4791000.00
ADN.TO income_statement (annual, 2023-12-31) — Basic Average Shares: 17123919.00
ADN.TO income_statement (annual, 2023-12-31) — Basic EPS: 1.72
ADN.TO cash_flow (annual, 2023-12-31) — Beginning Cash Position: 6230000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Capital Stock: 147618000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 1831000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 1831000.00
ADN.TO cash_flow (annual, 2023-12-31) — Cash Dividends Paid: -14868000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Cash Financial: 1831000.00
ADN.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -14868000.00
ADN.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: 56000.00
ADN.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: 10413000.00
ADN.TO cash_flow (annual, 2023-12-31) — Change In Inventory: 514000.00
ADN.TO cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -326000.00
ADN.TO cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: -1836000.00
ADN.TO cash_flow (annual, 2023-12-31) — Change In Receivables: -1036000.00
ADN.TO cash_flow (annual, 2023-12-31) — Change In Working Capital: -2684000.00
ADN.TO cash_flow (annual, 2023-12-31) — Changes In Account Receivables: -1036000.00
ADN.TO cash_flow (annual, 2023-12-31) — Changes In Cash: -4399000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Common Stock: 147618000.00
ADN.TO cash_flow (annual, 2023-12-31) — Common Stock Dividend Paid: -14868000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Common Stock Equity: 318982000.00
ADN.TO income_statement (annual, 2023-12-31) — Cost Of Revenue: 63895000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Current Assets: 28129000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Current Liabilities: 14353000.00
ADN.TO cash_flow (annual, 2023-12-31) — Deferred Income Tax: 10611000.00
ADN.TO cash_flow (annual, 2023-12-31) — Deferred Tax: 10611000.00
ADN.TO cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 363000.00
ADN.TO income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 363000.00
ADN.TO cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 363000.00
ADN.TO income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 363000.00
ADN.TO income_statement (annual, 2023-12-31) — Diluted Average Shares: 17123919.00
ADN.TO income_statement (annual, 2023-12-31) — Diluted EPS: 1.72
ADN.TO income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: 29434000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Dividends Payable: 4983000.00
ADN.TO income_statement (annual, 2023-12-31) — EBIT: 43198000.00
ADN.TO income_statement (annual, 2023-12-31) — EBITDA: 43561000.00
ADN.TO cash_flow (annual, 2023-12-31) — End Cash Position: 1831000.00
ADN.TO cash_flow (annual, 2023-12-31) — Financing Cash Flow: -14868000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Fixed Assets Revaluation Reserve: 33867000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Foreign Currency Translation Adjustments: 25873000.00
ADN.TO cash_flow (annual, 2023-12-31) — Free Cash Flow: 10413000.00
ADN.TO cash_flow (annual, 2023-12-31) — Gain Loss On Investment Securities: -22995000.00
ADN.TO cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of PPE: -657000.00
ADN.TO income_statement (annual, 2023-12-31) — Gain On Sale Of Ppe: 657000.00
ADN.TO income_statement (annual, 2023-12-31) — Gain On Sale Of Security: 22975000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: 59740000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 6140000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Gross PPE: 95645000.00
ADN.TO income_statement (annual, 2023-12-31) — Gross Profit: 29582000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Income Tax Payable: 0.00
ADN.TO income_statement (annual, 2023-12-31) — Interest Expense: 3153000.00
ADN.TO income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 3153000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Inventory: 15329000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Invested Capital: 424497000.00
ADN.TO cash_flow (annual, 2023-12-31) — Investing Cash Flow: 56000.00
ADN.TO cash_flow (annual, 2023-12-31) — Issuance Of Debt: 0.00
ADN.TO balance_sheet (annual, 2023-12-31) — Land And Improvements: 92591000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Long Term Debt: 105515000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 105515000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Net Debt: 103684000.00
ADN.TO income_statement (annual, 2023-12-31) — Net Income: 29434000.00
ADN.TO income_statement (annual, 2023-12-31) — Net Income Common Stockholders: 29434000.00
ADN.TO income_statement (annual, 2023-12-31) — Net Income Continuous Operations: 29434000.00
ADN.TO income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: 29434000.00
ADN.TO income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: 29434000.00
ADN.TO cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: 29434000.00
ADN.TO income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: 29434000.00
ADN.TO income_statement (annual, 2023-12-31) — Net Interest Income: -3153000.00
ADN.TO cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: 0.00
ADN.TO income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -3153000.00
ADN.TO cash_flow (annual, 2023-12-31) — Net Other Investing Changes: -619000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Net PPE: 90854000.00
ADN.TO cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: 675000.00
ADN.TO cash_flow (annual, 2023-12-31) — Net Short Term Debt Issuance: 0.00
ADN.TO balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 312842000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 129103000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 129103000.00
ADN.TO income_statement (annual, 2023-12-31) — Normalized EBITDA: 19929000.00
ADN.TO income_statement (annual, 2023-12-31) — Normalized Income: 12063934.12
ADN.TO cash_flow (annual, 2023-12-31) — Operating Cash Flow: 10413000.00
ADN.TO cash_flow (annual, 2023-12-31) — Operating Gains Losses: -23652000.00
ADN.TO income_statement (annual, 2023-12-31) — Operating Income: 19566000.00
ADN.TO income_statement (annual, 2023-12-31) — Operating Revenue: 93477000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 17182558.00
ADN.TO income_statement (annual, 2023-12-31) — Other Income Expense: 23632000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Other Inventories: 15329000.00
ADN.TO cash_flow (annual, 2023-12-31) — Other Non Cash Items: 20000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 442830000.00
ADN.TO income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 22975000.00
ADN.TO income_statement (annual, 2023-12-31) — Other Operating Expenses: 1526000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Other Properties: 3054000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Payables: 14353000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 14353000.00
ADN.TO income_statement (annual, 2023-12-31) — Pretax Income: 40045000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Properties: 0.00
ADN.TO balance_sheet (annual, 2023-12-31) — Receivables: 10969000.00
ADN.TO income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 63895000.00
ADN.TO income_statement (annual, 2023-12-31) — Reconciled Depreciation: 363000.00
ADN.TO cash_flow (annual, 2023-12-31) — Repayment Of Debt: 0.00
ADN.TO balance_sheet (annual, 2023-12-31) — Retained Earnings: 111624000.00
ADN.TO cash_flow (annual, 2023-12-31) — Sale Of PPE: 675000.00
ADN.TO income_statement (annual, 2023-12-31) — Selling General And Administration: 8127000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Share Issued: 17182558.00
ADN.TO cash_flow (annual, 2023-12-31) — Short Term Debt Issuance: 0.00
ADN.TO cash_flow (annual, 2023-12-31) — Short Term Debt Payments: 0.00
ADN.TO income_statement (annual, 2023-12-31) — Special Income Charges: 657000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Stockholders Equity: 318982000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Tangible Book Value: 312842000.00
ADN.TO income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 6261934.12
ADN.TO income_statement (annual, 2023-12-31) — Tax Provision: 10611000.00
ADN.TO income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.26
ADN.TO balance_sheet (annual, 2023-12-31) — Taxes Receivable: 1668000.00
ADN.TO cash_flow (annual, 2023-12-31) — Taxes Refund Paid: -3679000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Total Assets: 567953000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Total Capitalization: 424497000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Total Debt: 105515000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 318982000.00
ADN.TO income_statement (annual, 2023-12-31) — Total Expenses: 73911000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 248971000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 539824000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 234618000.00
ADN.TO income_statement (annual, 2023-12-31) — Total Operating Income As Reported: 19566000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Total Tax Payable: 0.00
ADN.TO income_statement (annual, 2023-12-31) — Total Unusual Items: 23632000.00
ADN.TO income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: 23632000.00
ADN.TO balance_sheet (annual, 2023-12-31) — Working Capital: 13776000.00
ADN.TO income_statement (quarterly, 2024-09-30) — Basic Average Shares: 17511464.00
ADN.TO income_statement (quarterly, 2024-09-30) — Basic EPS: 0.13
ADN.TO income_statement (quarterly, 2024-09-30) — Depreciation Amortization Depletion Income Statement: 139000.00
ADN.TO income_statement (quarterly, 2024-09-30) — Depreciation And Amortization In Income Statement: 139000.00
ADN.TO income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 17511464.00
ADN.TO income_statement (quarterly, 2024-09-30) — Diluted EPS: 0.13
ADN.TO cash_flow (quarterly, 2024-09-30) — Gain Loss On Investment Securities: 92000.00
ADN.TO cash_flow (quarterly, 2024-09-30) — Net Other Investing Changes: -291000.00
ADN.TO cash_flow (quarterly, 2024-09-30) — Net Short Term Debt Issuance: 0.00
ADN.TO balance_sheet (quarterly, 2024-09-30) — Other Current Borrowings: 43197000.00
ADN.TO cash_flow (quarterly, 2024-09-30) — Short Term Debt Issuance: 0.00
ADN.TO cash_flow (quarterly, 2024-09-30) — Short Term Debt Payments: 0.00
ADN.TO balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 0.00
ADN.TO income_statement (annual, 2024-12-31) — +Operating Expense: 14606000.00
ADN.TO income_statement (quarterly, 2024-12-31) — +Operating Expense: 2504000.00
ADN.TO income_statement (annual, 2024-12-31) — +Total Revenue: 116185000.00
ADN.TO income_statement (quarterly, 2024-12-31) — +Total Revenue: 20226000.00
ADN.TO balance_sheet (annual, 2024-12-31) — Accounts Payable: 10922000.00
ADN.TO balance_sheet (quarterly, 2024-12-31) — Accounts Payable: 10922000.00
ADN.TO balance_sheet (annual, 2024-12-31) — Accounts Receivable: 8576000.00